Metformin has also been shown to reduce the expression of high-sensitivity C-reactive protein, which is an inflammatory indicator that can demonstrate the progression of metabolic disorder in the plasma of type 2 diabetes mellitus patients.41 Metformin might decrease FGF21 levels by alleviating inflammation in type 2 diabetes mellitus patients. Here, FGF21 is linked to Other metabolic disease.